Akero Therapeutics Analyst Ratings
Akero Therapeutics Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/14/2023 | 186.74% | HC Wainwright & Co. | → $40 | Reiterates | Buy → Buy |
10/12/2023 | 179.57% | UBS | $83 → $39 | Maintains | Buy |
10/11/2023 | 193.91% | JP Morgan | $62 → $41 | Maintains | Overweight |
10/11/2023 | 186.74% | HC Wainwright & Co. | $64 → $40 | Maintains | Buy |
10/11/2023 | 179.57% | Cantor Fitzgerald | $69 → $39 | Maintains | Overweight |
10/11/2023 | 136.56% | Morgan Stanley | $70 → $33 | Maintains | Overweight |
10/04/2023 | 394.62% | Cantor Fitzgerald | → $69 | Reiterates | Overweight → Overweight |
09/19/2023 | 394.62% | Cantor Fitzgerald | → $69 | Initiates Coverage On | → Overweight |
09/13/2023 | 330.11% | Evercore ISI Group | $50 → $60 | Maintains | Outperform |
09/05/2023 | 344.44% | JP Morgan | $49 → $62 | Maintains | Overweight |
08/28/2023 | 494.98% | UBS | → $83 | Initiates Coverage On | → Buy |
06/12/2023 | 401.79% | Morgan Stanley | $65 → $70 | Maintains | Overweight |
06/07/2023 | 358.78% | HC Wainwright & Co. | $62 → $64 | Maintains | Buy |
05/17/2023 | 322.94% | Canaccord Genuity | $58 → $59 | Maintains | Buy |
05/16/2023 | 344.44% | HC Wainwright & Co. | $64 → $62 | Maintains | Buy |
03/21/2023 | 315.77% | Canaccord Genuity | $50 → $58 | Maintains | Buy |
03/20/2023 | 358.78% | HC Wainwright & Co. | → $64 | Reiterates | → Buy |
01/27/2023 | 365.95% | Morgan Stanley | → $65 | Upgrades | Equal-Weight → Overweight |
11/07/2022 | 186.74% | Morgan Stanley | $30 → $40 | Maintains | Equal-Weight |
11/07/2022 | 358.78% | HC Wainwright & Co. | $62 → $64 | Maintains | Buy |
09/14/2022 | 115.05% | Morgan Stanley | $26 → $30 | Maintains | Equal-Weight |
09/14/2022 | 258.42% | Evercore ISI Group | $10 → $50 | Upgrades | In-Line → Outperform |
11/15/2021 | 107.89% | Morgan Stanley | $27 → $29 | Maintains | Equal-Weight |
11/15/2021 | 344.44% | HC Wainwright & Co. | $64 → $62 | Maintains | Buy |
10/19/2021 | 93.55% | Morgan Stanley | → $27 | Downgrades | Overweight → Equal-Weight |
09/10/2021 | 186.74% | B of A Securities | → $40 | Initiates Coverage On | → Buy |
08/16/2021 | 358.78% | HC Wainwright & Co. | $68 → $64 | Maintains | Buy |
03/23/2021 | 351.61% | Morgan Stanley | $70 → $63 | Maintains | Overweight |
03/23/2021 | 387.46% | HC Wainwright & Co. | $61 → $68 | Maintains | Buy |
03/18/2021 | 229.75% | Canaccord Genuity | $51 → $46 | Maintains | Buy |
03/17/2021 | 480.65% | Chardan Capital | $79 → $81 | Maintains | Buy |
03/17/2021 | 337.28% | HC Wainwright & Co. | $64 → $61 | Maintains | Buy |
02/26/2021 | 287.1% | Guggenheim | → $54 | Initiates Coverage On | → Buy |
11/13/2020 | 358.78% | HC Wainwright & Co. | $62 → $64 | Maintains | Buy |
09/10/2020 | 401.79% | Morgan Stanley | → $70 | Initiates Coverage On | → Overweight |
07/20/2020 | 344.44% | HC Wainwright & Co. | $45 → $62 | Maintains | Buy |
07/07/2020 | 466.31% | Chardan Capital | → $79 | Initiates Coverage On | → Buy |
07/01/2020 | 222.58% | HC Wainwright & Co. | $33 → $45 | Maintains | Buy |
07/01/2020 | 244.09% | Jefferies | $31 → $48 | Maintains | Buy |
03/02/2020 | 136.56% | HC Wainwright & Co. | → $33 | Initiates Coverage On | → Buy |
02/10/2020 | 158.06% | Canaccord Genuity | → $36 | Initiates Coverage On | → Buy |
07/15/2019 | 100.72% | JP Morgan | → $28 | Initiates Coverage On | → Overweight |
07/15/2019 | 143.73% | Roth Capital | → $34 | Initiates Coverage On | → Buy |
07/15/2019 | 100.72% | Jefferies | → $28 | Initiates Coverage On | → Buy |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
11/14/2023 | 186.74% | HC Wainwright & Co. | → 40 美元 | 重申 | 购买 → 购买 |
2023 年 12 月 10 日 | 179.57% | 瑞银(UBS) | 83 美元 → 39 美元 | 维护 | 买 |
2023 年 11 月 10 日 | 193.91% | 摩根大通 | 62 美元 → 41 美元 | 维护 | 超重 |
2023 年 11 月 10 日 | 186.74% | HC Wainwright & Co. | 64 美元 → 40 美元 | 维护 | 买 |
2023 年 11 月 10 日 | 179.57% | 坎托·菲茨杰拉德 | 69 美元 → 39 美元 | 维护 | 超重 |
2023 年 11 月 10 日 | 136.56% | 摩根士丹利 | 70 美元 → 33 美元 | 维护 | 超重 |
2023 年 4 月 10 日 | 394.62% | 坎托·菲茨杰拉德 | → 69 美元 | 重申 | 超重 → 超重 |
09/19/2023 | 394.62% | 坎托·菲茨杰拉德 | → 69 美元 | 启动覆盖范围开启 | → 超重 |
09/13/2023 | 330.11% | Evercore ISI 集团 | 50 美元 → 60 美元 | 维护 | 跑赢大盘 |
09/05/2023 | 344.44% | 摩根大通 | 49 美元 → 62 美元 | 维护 | 超重 |
08/28/2023 | 494.98% | 瑞银(UBS) | → 83 美元 | 启动覆盖范围开启 | → 购买 |
06/12/2023 | 401.79% | 摩根士丹利 | 65 美元 → 70 美元 | 维护 | 超重 |
06/07/2023 | 358.78% | HC Wainwright & Co. | 62 美元 → 64 美元 | 维护 | 买 |
05/17/2023 | 322.94% | Canaccord Genu | 58 美元 → 59 美元 | 维护 | 买 |
05/16/2023 | 344.44% | HC Wainwright & Co. | 64 美元 → 62 美元 | 维护 | 买 |
03/21/2023 | 315.77% | Canaccord Genu | 50 美元 → 58 美元 | 维护 | 买 |
03/20/2023 | 358.78% | HC Wainwright & Co. | → 64 美元 | 重申 | → 购买 |
01/27/2023 | 365.95% | 摩根士丹利 | → 65 美元 | 升级 | 重量相等 → 超重 |
2022 年 7 月 11 日 | 186.74% | 摩根士丹利 | 30 美元 → 40 美元 | 维护 | 重量相等 |
2022 年 7 月 11 日 | 358.78% | HC Wainwright & Co. | 62 美元 → 64 美元 | 维护 | 买 |
09/14/2022 | 115.05% | 摩根士丹利 | 26 美元 → 30 美元 | 维护 | 重量相等 |
09/14/2022 | 258.42% | Evercore ISI 集团 | 10 美元 → 50 美元 | 升级 | 盘中 → 跑赢大盘 |
11/15/2021 | 107.89% | 摩根士丹利 | 27 美元 → 29 美元 | 维护 | 重量相等 |
11/15/2021 | 344.44% | HC Wainwright & Co. | 64 美元 → 62 美元 | 维护 | 买 |
10/19/2021 | 93.55% | 摩根士丹利 | → 27 美元 | 降级 | 超重 → 重量相等 |
2021 年 10 月 9 日 | 186.74% | B of A 类证券 | → 40 美元 | 启动覆盖范围开启 | → 购买 |
2021 年 8 月 16 日 | 358.78% | HC Wainwright & Co. | 68 美元 → 64 美元 | 维护 | 买 |
03/23/2021 | 351.61% | 摩根士丹利 | 70 美元 → 63 美元 | 维护 | 超重 |
03/23/2021 | 387.46% | HC Wainwright & Co. | 61 美元 → 68 美元 | 维护 | 买 |
03/18/2021 | 229.75% | Canaccord Genu | 51 美元 → 46 美元 | 维护 | 买 |
03/17/2021 | 480.65% | 查丹资本 | 79 美元 → 81 美元 | 维护 | 买 |
03/17/2021 | 337.28% | HC Wainwright & Co. | 64 美元 → 61 美元 | 维护 | 买 |
2021 年 2 月 26 日 | 287.1% | 古根海姆 | → 54 美元 | 启动覆盖范围开启 | → 购买 |
11/13/2020 | 358.78% | HC Wainwright & Co. | 62 美元 → 64 美元 | 维护 | 买 |
2020 年 10 月 9 日 | 401.79% | 摩根士丹利 | → 70 美元 | 启动覆盖范围开启 | → 超重 |
2020 年 7 月 20 日 | 344.44% | HC Wainwright & Co. | 45 美元 → 62 美元 | 维护 | 买 |
07/07/2020 | 466.31% | 查丹资本 | → 79 美元 | 启动覆盖范围开启 | → 购买 |
07/01/2020 | 222.58% | HC Wainwright & Co. | 33 美元 → 45 美元 | 维护 | 买 |
07/01/2020 | 244.09% | 杰富瑞集团 | 31 美元 → 48 美元 | 维护 | 买 |
03/02/2020 | 136.56% | HC Wainwright & Co. | → 33 美元 | 启动覆盖范围开启 | → 购买 |
2020 年 10 月 2 日 | 158.06% | Canaccord Genu | → 36 美元 | 启动覆盖范围开启 | → 购买 |
07/15/2019 | 100.72% | 摩根大通 | → 28 美元 | 启动覆盖范围开启 | → 超重 |
07/15/2019 | 143.73% | 罗斯资本 | → 34 美元 | 启动覆盖范围开启 | → 购买 |
07/15/2019 | 100.72% | 杰富瑞集团 | → 28 美元 | 启动覆盖范围开启 | → 购买 |
What is the target price for Akero Therapeutics (AKRO)?
Akero Therapeutics(AKRO)的目标价格是多少?
The latest price target for Akero Therapeutics (NASDAQ: AKRO) was reported by HC Wainwright & Co. on November 14, 2023. The analyst firm set a price target for $40.00 expecting AKRO to rise to within 12 months (a possible 186.74% upside). 18 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年11月14日公布了Akero Therapeutics(纳斯达克股票代码:AKRO)的最新目标股价。该分析公司将目标股价定为40.00美元,预计AKRO将在12个月内升至12个月内(可能上涨186.74%)。去年有18家分析公司公布了评级。
What is the most recent analyst rating for Akero Therapeutics (AKRO)?
Akero Therapeutics(AKRO)的最新分析师评级是多少?
The latest analyst rating for Akero Therapeutics (NASDAQ: AKRO) was provided by HC Wainwright & Co., and Akero Therapeutics reiterated their buy rating.
HC Wainwright & Co. 提供了Akero Therapeutics(纳斯达克股票代码:AKRO)的最新分析师评级,Akero Therapeutics重申了买入评级。
When is the next analyst rating going to be posted or updated for Akero Therapeutics (AKRO)?
Akero Therapeutics(AKRO)的下一份分析师评级何时发布或更新?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akero Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akero Therapeutics was filed on November 14, 2023 so you should expect the next rating to be made available sometime around November 14, 2024.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Akero Therapeutics的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。Akero Therapeutics的最新评级是在2023年11月14日公布的,因此您应该预计下一个评级将在2024年11月14日左右公布。
Is the Analyst Rating Akero Therapeutics (AKRO) correct?
分析师对Akero Therapeutics(AKRO)的评级是否正确?
While ratings are subjective and will change, the latest Akero Therapeutics (AKRO) rating was a reiterated with a price target of $0.00 to $40.00. The current price Akero Therapeutics (AKRO) is trading at is $13.95, which is within the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但重申了最新的Akero Therapeutics(AKRO)评级,目标股价为0.00美元至40.00美元。Akero Therapeutics(AKRO)目前的交易价格为13.95美元,在分析师的预测区间内。